cardiovascular-agents and Hemangioma

Infantile hemangioma (IH) is a type of benign tumor that develops during infancy and spontaneously involutes after 1 year of age. Before the introduction of propranolol in 2008, some patients with IH were instructed to wait for the involution without treatment. This long-term follow-up study was conducted to assess the prognosis of East-Asian children with untreated deep or mixed facial IH. Skin sequelae were assessed by comparing images obtained during the patients' first and last visits in our clinic. Possible factors were assessed for their association with IH prognosis. The mean follow-up time was 7.4 years. Among the 48 patients with deep or mixed facial IH, 26 (54%) achieved complete involution without sequelae and 22 encountered various sequelae, including telangiectasia (36.3%), fibrofatty residue (68.2%), and scars (4%). The complete regression rate of deep or mixed IH occurring in the central facial region was significantly lower than for those in the perifacial region (33.3% vs 66.7%, respectively, χ

Topics: Asian People; Cardiovascular Agents; Child; Child, Preschool; Conservative Treatment; Disease Progression; Face; Female; Follow-Up Studies; Hemangioma; Humans; Male; Prognosis; Propranolol; Remission, Spontaneous; Retrospective Studies; Skin; Skin Neoplasms; Watchful Waiting

A slow-involuting segmental haemangioma was initially treated conventionally. Proliferation recurred when treatment was stopped. When the effect of propranolol on haemangiomas was published, we treated this 2.5- year- old girl with it. The haemangioma finally regressed recorded on magnetic resonance imaging and at clinical follow-up.

Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Combined Modality Therapy; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Magnetic Resonance Imaging; Propranolol

Topics: Cardiovascular Agents; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol

To present a case series showing efficacious use of vincristine in treating Kasabach-Merritt syndrome (KMS).. The case notes of four children treated for KMS by the authors with corticosteroids and vincristine were reviewed. Specific attention was paid to the efficacy and adverse effects of each therapeutic agent.. The age of presentation ranged from birth to 11 months. Initial treatment with high dose corticosteroids was uniformly ineffective, and in 2 cases, prolonged use caused significant side-effects. Subsequent or concurrent treatment with vincristine was effective and well-tolerated, with no discernable side effects. The only complications were line-related.. Kasabach-Merritt syndrome is rare, but it is associated with significant morbidity and mortality. No definitive treatment regime has been established, but the authors suggest that vincristine should be considered a first-line agent, and that the use of systemic corticosteroids should not be routine.

Topics: Blood Coagulation Disorders; Cardiovascular Agents; Female; Glucocorticoids; Hemangioma; Humans; Infant; Infant, Newborn; Male; Vincristine

Topics: Arterial Occlusive Diseases; Cardiovascular Agents; Connective Tissue Diseases; Dyspnea; Hemangioma; HIV Infections; Humans; Hypertension, Pulmonary; Risk Factors